



Quidel *First Quarter Conference Call Alert*

April 11, 2002

SAN DIEGO, Apr 11, 2002 /PRNewswire-FirstCall via COMTEX/ -- Quidel Corporation (Nasdaq: QDEL), a worldwide leader in developing, manufacturing and marketing point-of-care (POC) rapid diagnostic tests for the detection and management of a variety of medical conditions and illnesses, today announced that it will release 2002 first quarter results after market close on Tuesday, April 30, at 4:10 p.m. ET (1:10 p.m. PT).

S. Wayne Kay, President and Chief Executive Officer, and Paul E. Landers, Vice President and Chief Financial Officer, will be hosting an investment-community conference call beginning at 5:00 p.m. ET (2:00 p.m. PT) on Tuesday, April 30, 2002 to discuss those results and to answer questions.

To participate in the live call by telephone, please dial (888) 803-7383 from the U.S., or for international callers, please dial (706) 634-1052.

Those interested in listening to the conference call live via the Internet may do so by visiting the Company's Web site at www.quidel.com. To listen to the live call, please go to the Website 15 minutes prior to its start to register, download, and install the necessary audio software.

A replay will be available on Quidel's Web site for 14 days. A telephone replay will be available for 14 days by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering reservation number 3828377.

About Quidel

Quidel Corporation discovers, develops, manufactures and markets rapid point-of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health, in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia, infectious mononucleosis and bacterial vaginosis. Quidel's products are sold to healthcare professionals for use in physicians' offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information to enable rapid treatment and improve health outcomes, lower costs and increase patient satisfaction. For more information, please visit Quidel's Web site at www.quidel.com.

SOURCE Quidel Corporation

CONTACT:

Martin Halsall, mhalsall@lhai.com, or Bruce Voss, bvoss@lhai.com, both of Lippert/Heilshorn & Associates, +1-310-691-7100, for Quidel Corporation; or Paul E. Landers, Vice President & CFO of Quidel Corporation, +1-858-552-7962